← Back to Search

PARP Inhibitor

Olaparib + Vitamin C for Prostate Cancer

Phase 2
Recruiting
Led By Channing Paller, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a combination of a drug that stops cancer cells from fixing themselves and high doses of vitamin C in prostate cancer patients who do not respond to standard hormone therapy and lack certain genetic mutations. The goal is to see if this combination can reduce cancer markers and improve survival.

Who is the study for?
Men over 18 with castration-resistant prostate cancer, who have progressed after one systemic treatment. They must have a PSA of at least 1 ng/mL, good performance status (able to carry out daily activities), and normal organ/marrow function. Contraception is required for men and their partners. Exclusions include prior PARP inhibitors use, recent major surgery or chemotherapy, strong CYP3A inducers use, uncontrolled heart conditions, active hepatitis or HIV.
What is being tested?
The trial tests the combination of Olaparib (a PARP inhibitor) and high-dose IV Vitamin C in treating prostate cancer without DNA repair gene mutations. It measures the reduction in PSA levels by half from baseline as the main outcome and looks at safety through incidence of severe toxicities.
What are the potential side effects?
Possible side effects may include nausea, fatigue, anemia (low red blood cell counts), potential kidney issues due to creatinine levels changes; allergic reactions are possible given it's a drug study but specific side effects will be monitored closely.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PSA50 response
Secondary study objectives
Overall survival of patients with mCRPC receiving olaparib in combination with IV ascorbic acid
PSA doubling time in patients with mCRPC receiving olaparib in combination with IV ascorbic acid
PSA progression free survival (PSA PFS) of patients with mCRPC receiving olaparib in combination with IV ascorbic acid
+2 more

Side effects data

From 2023 Phase 3 trial • 154 Patients • NCT02184195
49%
Nausea
47%
Fatigue
38%
Diarrhoea
29%
Abdominal pain
29%
Anaemia
28%
Constipation
27%
Decreased appetite
27%
Back pain
26%
Vomiting
21%
Arthralgia
19%
Pyrexia
18%
Asthenia
13%
Rash
13%
Nasopharyngitis
11%
Alanine aminotransferase increased
11%
Dyspnoea
10%
Neuropathy peripheral
10%
Cough
10%
Abdominal pain upper
10%
Dyspepsia
10%
Anxiety
10%
Pruritus
9%
Aspartate aminotransferase increased
9%
Hyperglycaemia
9%
Dizziness
9%
Thrombocytopenia
9%
Oedema peripheral
9%
Pain in extremity
9%
Insomnia
9%
Stomatitis
9%
Dry mouth
9%
Headache
9%
Neutropenia
8%
Blood creatinine increased
8%
Weight decreased
7%
Dysgeusia
7%
Blood alkaline phosphatase increased
7%
Neutrophil count decreased
7%
Muscle spasms
7%
Influenza
7%
Influenza like illness
7%
Myalgia
7%
Peripheral sensory neuropathy
7%
Gamma-glutamyltransferase increased
6%
Hypertension
6%
Platelet count decreased
6%
Depression
6%
Lymphopenia
6%
Gastrooesophageal reflux disease
6%
Abdominal distension
5%
Musculoskeletal pain
3%
Flank pain
2%
Cholangitis
2%
Flatulence
2%
Paraesthesia
1%
General physical health deterioration
1%
Bladder papilloma
1%
Pneumonia pneumococcal
1%
Abdominal infection
1%
Bartholinitis
1%
Pneumonia
1%
Cerebrovascular accident
1%
Pneumothorax
1%
Gastric varices haemorrhage
1%
Large intestinal obstruction
1%
Cholecystitis
1%
Anastomotic haemorrhage
1%
Device occlusion
1%
Stent malfunction
1%
Bronchiolitis
1%
Empyema
1%
Syncope
1%
Incisional hernia
1%
Device dislocation
1%
Obstruction gastric
1%
Cardiac failure
1%
Vascular stenosis
1%
Pleural effusion
1%
Incarcerated inguinal hernia
1%
Urinary tract infection
1%
Hypothyroidism
1%
Transient ischaemic attack
1%
Infusion related reaction
1%
Duodenal perforation
1%
Melaena
1%
Bile duct obstruction
1%
Pancreatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Olaparib 300 mg Twice Daily (bd)
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: Olaparib and Vitamin CExperimental Treatment2 Interventions
Olaparib will be administered at 300 mg by mouth, twice daily; ascorbate will be administered at 1 g/kg IV twice weekly at least 24 hours apart, until objective disease progression or unacceptable toxicities or patient withdrawal for other reasons.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Olaparib
2007
Completed Phase 4
~2190
Vitamin C
2017
Completed Phase 4
~18470

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for prostate cancer include androgen deprivation therapy (ADT), androgen receptor antagonists, and PARP inhibitors like Olaparib. ADT reduces androgen levels, which prostate cancer cells rely on for growth. Androgen receptor antagonists, such as enzalutamide, block the androgen receptor signaling pathway, preventing cancer cell proliferation. PARP inhibitors, like Olaparib, target cancer cells with DNA repair deficiencies by inhibiting the PARP enzyme, leading to cell death. High-dose IV ascorbate induces oxidative stress, damaging cancer cell DNA. These treatments are crucial as they target specific mechanisms that prostate cancer cells depend on, offering tailored and effective therapeutic options.

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
569 Previous Clinical Trials
33,425 Total Patients Enrolled
57 Trials studying Prostate Cancer
3,413 Patients Enrolled for Prostate Cancer
AstraZenecaIndustry Sponsor
4,368 Previous Clinical Trials
288,736,682 Total Patients Enrolled
59 Trials studying Prostate Cancer
27,717 Patients Enrolled for Prostate Cancer
McGuff Pharmaceuticals, Inc.Industry Sponsor
3 Previous Clinical Trials
128 Total Patients Enrolled

Media Library

Olaparib (PARP Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05501548 — Phase 2
Prostate Cancer Research Study Groups: Olaparib and Vitamin C
Prostate Cancer Clinical Trial 2023: Olaparib Highlights & Side Effects. Trial Name: NCT05501548 — Phase 2
Olaparib (PARP Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05501548 — Phase 2
~10 spots leftby Mar 2028